More Than 28 Cups of Coffee a Week May Endanger Health in Under-55s
Younger people should avoid heavy coffee consumption, suggests new study
published in Mayo Clinic Proceedings
Younger people should avoid heavy coffee consumption, suggests new study
Rochester, MN, August 15, 2013
Nearly 400 million cups of coffee are consumed every day in America. Drinking large amounts of coffee may be bad for under-55s, according to a new study published in Mayo Clinic Proceedings. A study of more than 40,000 individuals found a statistically significant 21% increased mortality in those drinking more than 28 cups of coffee a week and death from all causes, with a greater than 50% increased mortality risk in both men and women younger than 55 years of age. Investigators warn that younger people in particular may need to avoid heavy coffee consumption. No adverse effects were found in heavy coffee drinkers aged over 55.
Drinking coffee has become a normal daily routine for large numbers of people worldwide. According to the latest National Coffee Drinking Study from the National Coffee Association, more than 60% of American adults drink coffee every day, consuming on average just over three cups a day.
Coffee has long been suspected to contribute to a variety of chronic health conditions, although earlier studies on coffee consumption in relation to deaths from all causes and deaths from coronary heart disease are limited, and the results are often controversial.
A multicenter research team investigated the effect of coffee consumption on death from all causes and deaths from cardiovascular disease in the Aerobics Center Longitudinal Study (ACLS) cohort, with an average follow-up period of 16 years and a relatively large sample size of over 40,000 men and women.
Between 1979 and 1998, nearly 45,000 individuals aged between 20 and 87 years old participated and returned a medical history questionnaire assessing lifestyle habits (including coffee consumption) and personal and family medical history. The investigators examined a total of 43,727 participants (33,900 men and 9,827 women) in their final analysis.
During the 17-year median follow-up period there were 2,512 deaths (men: 87.5%; women: 12.5%), 32% of these caused by cardiovascular disease. Those who consumed higher amounts of coffee (both men and women) were more likely to smoke and had lower levels of cardiorespiratory fitness.
All participants were followed from the baseline examination to date of death or until December 31, 2003. Deaths from all causes and deaths from cardiovascular disease were identified through the National Death Index or by accessing death certificates.
Younger men had a trend towards higher mortality even at lower consumption, but this became significant at about 28 cups per week where there was a 56% increase in mortality from all causes. Younger women who consumed more than 28 cups of coffee per week also had a greater than 2-fold higher risk of all-cause mortality than those who did not drink coffee.
Senior investigator Steven H. Blair, PED, of the Department of Biostatistics and Epidemiology, Arnold School of Public Health, University of South Carolina, emphasizes that “Significantly, the results did not demonstrate any association between coffee consumption and all-cause mortality among older men and women. It is also important to note that none of the doses of coffee in either men or women whether younger or older had any significant effects on cardiovascular mortality.”
Coffee is a complex mixture of chemicals consisting of thousands of components. Recent research has found that coffee is one of the major sources of antioxidants in the diet and has potential beneficial effects on inflammation and cognitive function. However, it is also well-known that coffee has potential adverse effects because of caffeine’s potential to stimulate the release of epinephrine, inhibit insulin activity, and increase blood pressure and levels of homocysteine.
“Thus, all of these mechanisms could counterbalance one another. Research also suggests that heavy coffee drinkers may experience additional risk through potential genetic mechanisms or because of confounding through the deleterious effects of other risk factors with which coffee drinking is associated,” say lead authors, Junxiu Liu, MD, Department of Biostatistics and Epidemiology, and Xuemei Sui, MD, MPH, PhD, Department of Exercise Science, both at the Arnold School of Public Health, University of South Carolina, “Therefore, we hypothesize that the positive association between coffee and mortality may be due to the interaction of age and coffee consumption, combined with a component of genetic coffee addiction.”
The investigators suggest that younger people in particular should avoid heavy coffee consumption of more than 28 cups a week or four cups in a typical day. However, they emphasize that further studies are needed in different populations to assess details regarding the effects of long-term coffee consumption and changes in coffee consumption over time on all-cause and cardiovascular disease mortality.
Leading expert Carl J. Lavie, MD, of the Department of Cardiovascular Diseases, Ochsner Medical Center, New Orleans, and a co-author of this study, explains that “There continues to be considerable debate about the health effects of caffeine, and coffee specifically, with some reports suggesting toxicity and some even suggesting beneficial effects.”
# # #
Notes for Editors
“Association of Coffee Consumption with All-Cause and Cardiovascular Disease Mortality,” by Junxiu Liu, MD, Xuemei Sui, MD, MPH, PhD, Carl J. Lavie, MD, James R. Hebert, ScD, Conrad Earnest, PhD, Jiajia Zhang, PhD, and Steven N. Blair, PED (DOI: 10.1016/j.mayocp.2013.06.020). Mayo Clinic Proceedings, Volume 88, Issue 10 (October 2013), published by Elsevier.
Full text of the article is available to credentialed journalists upon request. Contact Rachael Zaleski at +1 215 239 3658 or email@example.com to obtain copies. To view an accompanying video presented by Dr. Carl Lavie go to http://bit.ly/14EJzvQ (under embargo) or http://youtu.be/Y0wwDSBwVqU once the embargo has lifted.
Journalists wishing to interview the authors may contact:
Carl J. Lavie, MD
Medical Director, Cardiac Rehabilitation and Prevention, Director, Stress Testing Laboratory
John Ochsner Heart and Vascular Institute
Ochsner Clinical School, The University of Queensland School of Medicine
+1 504 842 5874
Xuemei Sui, MD, MPH, PhD
Department of Exercise Science
Arnold School of Public Health, University of South Carolina
+1 803 777 3881
About Mayo Clinic Proceedings
The flagship journal of Mayo and one of the premier peer-reviewed clinical journals in general medicine, Mayo Clinic Proceedings is among the most widely read and highly cited scientific publications for physicians, with a circulation of approximately 125,000. While the Journal is sponsored by Mayo Clinic, it welcomes submissions from authors worldwide, publishing articles that focus on clinical medicine and support the professional and educational needs of its readers. www.mayoclinicproceedings.org
About Mayo Clinic
Mayo Clinic is a nonprofit worldwide leader in medical care, research, and education for people from all walks of life. For more information visit www.mayoclinic.org/about and www.mayoclinic.org/news.
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. www.elsevier.com
+1 215 239 3658